Plenary Keynotes - Immuno-Oncology Summit 2018

2019 Archived Content

Plenary Keynotes

Tuesday, August 6, 2019 | 4:15 - 5:30 pm

Harbor II & III

PANEL DISCUSSION: Next-Generation Immunotherapies

CHI’s Immuno-Oncology Summit brings you the latest advances in immunotherapy every year. This panel of industry thought leaders will discuss the technology advances and implementation strategies for next-generation immunotherapies, including emerging immunotherapy combinations, bispecific antibodies, oncolytic virotherapy, adoptive cell therapy, personalized vaccines and neoantigen targeted therapies, small molecules and ADCs, cytokines, and innate immunity targeted therapies.

Moderator

Pamela Carroll, PhD

Senior Vice President, Immuno-Oncology, Genocea Biosciences

Panelists

Rakesh Dixit

PhD, DABT, President & CEO, Bionavigen

Tara Arvedson, PhD

Director, Oncology Research, Amgen

Michael A. Curran, PhD

Associate Professor, MD Anderson Cancer Center; President, Immunogenesis, Inc.

Raymond Tesi, MD

CEO/CMO, INmune Bio

David Kirn, MD

Co-Founder & Executive Chairman, IGNITE Immunotherapy

Thursday, August 8, 2019 | 8:25 - 9:30 am

Harbor II

PANEL DISCUSSION: Partnering and Licensing in Immuno-Oncology

Big pharma and biotech are under pressure to compete in the booming Immuno-Oncology market and to capitalize on new technologies and innovations to bring next-generation immunotherapies to the patients. This insider panel will share what they look for in a partner or investment, and discuss opportunities for collaboration or in-licensing of novel immunotherapies, IO targets or biomarkers, and potential combination therapies.

Moderator

Griffith_Melinda Melinda Griffith, JD